SBRT Pre-operatively for Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Pancreatic Neoplasms
Interventions
RADIATION

5-fraction stereotactic body radiation therapy

"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV\_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV\_R) 10Gy/# (total dose 50Gy)"

Trial Locations (5)

Unknown

The Beatson West of Scotland Cancer Centre, Glasgow

St James' Hospital, Leeds

Northern Centre for Cancer Care, The Freeman Hospital, Newcastle

City Hospital, Nottingham

The Churchill Hospital, Oxford University Hospitals Trust, Oxford

All Listed Sponsors
collaborator

Oncology Clinical Trials Office

UNKNOWN

collaborator

Centre for Statistics in Medicine

OTHER

collaborator

CRUK/MRC Oxford Institute for Radiation Oncology

UNKNOWN

collaborator

University of Leeds

OTHER

lead

University of Oxford

OTHER

NCT02308722 - SBRT Pre-operatively for Pancreatic Cancer | Biotech Hunter | Biotech Hunter